The effectiveness and safety of fluoroquinolone-containing regimen as a first-line treatment for drug-sensitive pulmonary tuberculosis: A systematic review and meta-analysis

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Lee, Hyun Woo ^a   Lee, Jung Kyu ^b   Kim, Eunyoung ^c   Yim, Jae Joon ^a   Lee, Chang Hoon ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University Boramae Hospital   (South Korea)

^c Kyungpook National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ARTHRALGIA; ARTICLE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; LUNG TUBERCULOSIS; META ANALYSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SPUTUM CULTURE; SYSTEMATIC REVIEW; COMBINATION DRUG THERAPY; MEDICATION COMPLIANCE; MICROBIOLOGY; MORTALITY; ODDS RATIO; RECURRENT DISEASE; SPUTUM; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

ANTITUBERCULAR AGENTS; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HUMANS; MEDICATION ADHERENCE; ODDS RATIO; RECURRENCE; SPUTUM; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84980000135     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159827     Document Type: Article

References (30)

1. Organization WH (2014) Global tuberculosis control: WHO report 2014. Geneva: World Health Organization.
2. Combs DL, O'Brien RJ, Geiter LJ (1990) USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 112: 397-406. PMID: 2155569
3. Chaulk CP, Kazandjian VA (1998) Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel. Jama 279: 943-948. PMID: 9544769
4. Cuneo WD, Snider DE Jr. (1989) Enhancing patient compliance with tuberculosis therapy. Clin Chest Med 10: 375-380. PMID: 2673646
5. Karumbi J, Garner P (2015) Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 5: Cd003343. doi: 10.1002/14651858.CD003343.pub4 PMID: 26022367
6. East African and British Medical Research Councils (1978) Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis. First report of 4th study. Lancet 2: 334-338.
7. Hong Kong Chest Service/British Medical Research Council (1991) Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide. Results at 30 months. Am Rev Respir Dis 143: 700-706. PMID: 1901199
8. Pletz MW, De Roux A, Roth A, Neumann KH, Mauch H, Lode H (2004) Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 48: 780-782. PMID: 14982764
9. Hu Y, Coates AR, Mitchison DA (2003) Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 653-657. PMID: 12543673
10. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, et al. (2004) Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 169: 1103-1109. PMID: 14742301
11. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. (1993) Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328: 527-532. PMID: 8426619
12. Kohno S, Koga H, Kaku M, Maesaki S, Hara K (1992) Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis. Chest 102: 1815-1818. PMID: 1446494
13. Narayanan P (2002) Shortening short course chemotherapy: a randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberc 49: 27-38.
14. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, et al. (2008) A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 12: 128-138. PMID: 18230244
15. Conde MB, Efron A, Loredo C, De Souza GRM, Graca NP, Cezar MC, et al. (2009) Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. The Lancet 373: 1183-1189.
16. Ziganshina LE, Titarenko AF, Davies GR (2013) Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev 6: Cd004795. doi: 10.1002/14651858.CD004795.pub4 PMID: 23744519
17. Chen Z, Liang JQ, Wang JH, Feng SS, Zhang GY (2015) Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis. Tuberculosis (Edinb) 95: 490-496.
18. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. (2014) High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371: 1599-1608. doi: 10.1056/NEJMoa1314210 PMID: 25337749
19. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. (2014) A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371: 1588-1598. doi: 10.1056/NEJMoa1315817 PMID: 25337748
20. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. (2014) Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371: 1577-1587. doi: 10.1056/NEJMoa1407426 PMID: 25196020
21. Jawahar MS, Banurekha VV, Paramasivan CN, Rahman F, Ramachandran R, Venkatesan P, et al. (2013) Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regimens in the treatment of new sputum positive pulmonary tuberculosis patients. PLoS One 8: e67030. doi: 10.1371/journal.pone.0067030 PMID: 23843980
22. Velayutham BV, Allaudeen IS, Sivaramakrishnan GN, Perumal V, Nair D, Chinnaiyan P, et al. (2014) Sputum culture conversion with moxifloxacin-containing regimens in the treatment of patients with newly diagnosed sputum-positive pulmonary tuberculosis in South India. Clin Infect Dis 59: e142-149. doi: 10.1093/cid/ciu550 PMID: 25028463
23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151: W65-94. PMID: 19622512
24. el-Sadr WM, Perlman DC, Matts JP, Nelson ET, Cohn DL, Salomon N, et al. (1998) Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG). Clin Infect Dis 26: 1148-1158. PMID: 9597244
25. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, et al. (2006) Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 174: 331-338. PMID: 16675781
26. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al. (2009) Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 180: 273-280. doi: 10.1164/rccm.200901-0078OC PMID: 19406981
27. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, et al. (2000) A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 45: 859-870. PMID: 10837441
28. Wallis RS, Peppard T, Hermann D (2015) Month 2 culture status and treatment duration as predictors of recurrence in pulmonary tuberculosis: model validation and update. PLoS One 10: e0125403. doi: 10.1371/journal.pone.0125403 PMID: 25923700
29. Cox H, Ford N, Keshavjee S, McDermid C, von Schoen-Angerer T, Mitnick C, et al. (2011) Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis 11: 259-260. doi: 10.1016/S1473-3099(11)70036-6 PMID: 21453864
30. Mitnick CD, McGee B, Peloquin CA (2009) Tuberculosis pharmacotherapy: strategies to optimize patient care. Expert Opin Pharmacother 10: 381-401. doi: 10.1517/14656560802694564 PMID: 19191677